EICHORPublic-registry site landscape for NCT03138083, “OMO-1 in Solid Malignancies”, a Neoplasms study sponsored by Octimet Oncology N.V.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03138083 (registry record) |
| Study title | OMO-1 in Solid Malignancies |
| Official title | A Modular, Multi-arm, Multi-part, First Time in Patient Study to Evaluate the Safety and Tolerability of OMO-1, Alone and in Combination With Anti-cancer Treatments, in Patients With Locally Advanced, Unresectable or Metastatic Solid Malignancies |
| Sponsor | Octimet Oncology N.V. |
| Condition(s) | Neoplasms |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 11 |
| Intervention(s) | OMO-1 |
| Site countries | United States, Belgium, France, Netherlands, United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT03138083.
Eichor generates a preliminary site-risk snapshot for NCT03138083 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
